Kenneth Bate sold $6.9M of Madrigal Pharmaceuticals (MDGL)

Executed Feb 27 2025, disclosed Feb 28 2025, 1 day later.

Value, as filed

$6.9M

19,446 sh across 6 lots

Executed

Feb 27 2025

the trade date, as filed

Disclosed

Feb 28 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Kenneth Bate Director profile →

Kenneth Bate (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Madrigal Pharmaceuticals, Inc. (MDGL). The largest single filing was $8.0M of MDGL (16,545 sh across 10 lots, as filed), executed Nov 5 2025.

The name

MDGL

Madrigal Pharmaceuticals, Inc. MDGL · Healthcare · 59 filings in 24 months ticker →

Healthcare · Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Kenneth Bate in MDGL

MDGLSALE Madrigal Pharmaceuticals, Inc. $8.0M
16,545 sh across 10 lots
Exec Nov 5 2025
Filed Nov 7 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. $3.7M
10,000 sh across 6 lots
Exec Aug 15 2025
Filed Aug 15 2025 · 5:30 PM ET